Cost-effectiveness analysis of gender-stratified Plasmodium vivax treatment strategies using available g6pd diagnostics to accelerate access to radical cure
Tafenoquine has been licensed for the single-dose radical cure of Plasmodium vivax in adults; however, it is only recommended in patients with > 70% of normal glucose-6-phosphate dehydrogenase (G6PD) activity. Because this may hinder widespread use, we investigated gender-based treatment strategi...
| Egile Nagusiak: | , , , , , , , |
|---|---|
| Formatua: | Journal article |
| Hizkuntza: | English |
| Argitaratua: |
American Society of Tropical Medicine and Hygiene
2020
|